• Something wrong with this record ?

Assessment of urinary 6-oxo-pipecolic acid as a biomarker for ALDH7A1 deficiency

Y. Khalil, E. Footitt, R. Vootukuri, MF. Wempe, CR. Coughlin, S. Batzios, MP. Wilson, V. Kožich, PT. Clayton, PB. Mills

. 2025 ; 48 (1) : e12783. [pub] 20240722

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc25002945

Grant support
R21HD104952 Eunice Kennedy Shriver National Institute of Child Health & Human Development
R21 HD104952 NICHD NIH HHS - United States
AZV NU23-07-00383 Ministry of Health of the Czech Republic
RVO-VFN64165 Ministry of Health of the Czech Republic
Charles University

ALDH7A1 deficiency is an epileptic encephalopathy whose seizures respond to treatment with supraphysiological doses of pyridoxine. It arises as a result of damaging variants in ALDH7A1, a gene in the lysine catabolism pathway. α-Aminoadipic semialdehyde (α-AASA) and Δ1-piperideine-6-carboxylate (P6C), which accumulate because of the block in the lysine pathway, are diagnostic biomarkers for this disorder. Recently, it has been reported that 6-oxo-pipecolic acid (6-oxo-PIP) also accumulates in the urine, CSF and plasma of ALDH7A1-deficient individuals and that, given its improved stability, it may be a more suitable biomarker for this disorder. This study measured 6-oxo-PIP in urine from a cohort of 30 patients where α-AASA was elevated and showed that it was above the normal range in all those above 6 months of age. However, 6-oxo-PIP levels were within the normal range in 33% of the patients below 6 months of age. Levels increased with age and correlated with a decrease in α-AASA levels. Longitudinal analysis of urine samples from ALDH7A1-deficient patients who were on a lysine restricted diet whilst receiving supraphysiological doses of pyridoxine showed that levels of 6-oxo-PIP remained elevated whilst α-AASA decreased. Similar to α-AASA, we found that elevated urinary excretion of 6-oxo-PIP can also occur in individuals with molybdenum cofactor deficiency. This study demonstrates that urinary 6-oxo-PIP may not be a suitable biomarker for ALDH7A1 deficiency in neonates. However, further studies are needed to understand the biochemistry leading to its accumulation and its potential long-term side effects.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002945
003      
CZ-PrNML
005      
20250206103950.0
007      
ta
008      
250121s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jimd.12783 $2 doi
035    __
$a (PubMed)39038845
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Khalil, Youssef $u Genetics and Genomic Medicine, University College London Great Ormond Street Institute of Child Health, London, UK $1 https://orcid.org/0000000190253017
245    10
$a Assessment of urinary 6-oxo-pipecolic acid as a biomarker for ALDH7A1 deficiency / $c Y. Khalil, E. Footitt, R. Vootukuri, MF. Wempe, CR. Coughlin, S. Batzios, MP. Wilson, V. Kožich, PT. Clayton, PB. Mills
520    9_
$a ALDH7A1 deficiency is an epileptic encephalopathy whose seizures respond to treatment with supraphysiological doses of pyridoxine. It arises as a result of damaging variants in ALDH7A1, a gene in the lysine catabolism pathway. α-Aminoadipic semialdehyde (α-AASA) and Δ1-piperideine-6-carboxylate (P6C), which accumulate because of the block in the lysine pathway, are diagnostic biomarkers for this disorder. Recently, it has been reported that 6-oxo-pipecolic acid (6-oxo-PIP) also accumulates in the urine, CSF and plasma of ALDH7A1-deficient individuals and that, given its improved stability, it may be a more suitable biomarker for this disorder. This study measured 6-oxo-PIP in urine from a cohort of 30 patients where α-AASA was elevated and showed that it was above the normal range in all those above 6 months of age. However, 6-oxo-PIP levels were within the normal range in 33% of the patients below 6 months of age. Levels increased with age and correlated with a decrease in α-AASA levels. Longitudinal analysis of urine samples from ALDH7A1-deficient patients who were on a lysine restricted diet whilst receiving supraphysiological doses of pyridoxine showed that levels of 6-oxo-PIP remained elevated whilst α-AASA decreased. Similar to α-AASA, we found that elevated urinary excretion of 6-oxo-PIP can also occur in individuals with molybdenum cofactor deficiency. This study demonstrates that urinary 6-oxo-PIP may not be a suitable biomarker for ALDH7A1 deficiency in neonates. However, further studies are needed to understand the biochemistry leading to its accumulation and its potential long-term side effects.
650    _2
$a lidé $7 D006801
650    12
$a biologické markery $x moč $7 D015415
650    12
$a kyseliny pipekolové $x moč $7 D010875
650    _2
$a kojenec $7 D007223
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a předškolní dítě $7 D002675
650    _2
$a kyselina 2-aminoadipová $x moč $x analogy a deriváty $7 D015074
650    _2
$a dítě $7 D002648
650    _2
$a aldehyddehydrogenasa $x nedostatek $x genetika $7 D000444
650    _2
$a lysin $x nedostatek $x moč $7 D008239
650    _2
$a mitochondriální aldehyddehydrogenasa $x nedostatek $x genetika $7 D000071396
650    _2
$a pyridoxin $x nedostatek $x moč $x terapeutické užití $7 D011736
650    _2
$a novorozenec $7 D007231
650    _2
$a epilepsie $x moč $7 D004827
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Footitt, Emma $u Department of Metabolic Paediatrics, Great Ormond Street Hospital, London, UK
700    1_
$a Vootukuri, Reddy $u Genetics and Genomic Medicine, University College London Great Ormond Street Institute of Child Health, London, UK
700    1_
$a Wempe, Michael F $u School of Pharmacy, Department of Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA
700    1_
$a Coughlin, Curtis R $u Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado School of Medicine, Aurora, Colorado, USA
700    1_
$a Batzios, Spyros $u Department of Metabolic Paediatrics, Great Ormond Street Hospital, London, UK
700    1_
$a Wilson, Matthew P $u Genetics and Genomic Medicine, University College London Great Ormond Street Institute of Child Health, London, UK $u Laboratory for Molecular Diagnosis, Center for Human Genetics, KU Leuven, Leuven, Belgium
700    1_
$a Kožich, Viktor $u Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Clayton, Peter T $u Genetics and Genomic Medicine, University College London Great Ormond Street Institute of Child Health, London, UK
700    1_
$a Mills, Philippa B $u Genetics and Genomic Medicine, University College London Great Ormond Street Institute of Child Health, London, UK $1 https://orcid.org/0000000297041268
773    0_
$w MED00002747 $t Journal of inherited metabolic disease $x 1573-2665 $g Roč. 48, č. 1 (2025), s. e12783
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39038845 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103946 $b ABA008
999    __
$a ok $b bmc $g 2263001 $s 1238952
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 48 $c 1 $d e12783 $e 20240722 $i 1573-2665 $m Journal of inherited metabolic disease $n J Inherit Metab Dis $x MED00002747
GRA    __
$a R21HD104952 $p Eunice Kennedy Shriver National Institute of Child Health & Human Development
GRA    __
$a R21 HD104952 $p NICHD NIH HHS $2 United States
GRA    __
$a AZV NU23-07-00383 $p Ministry of Health of the Czech Republic
GRA    __
$a RVO-VFN64165 $p Ministry of Health of the Czech Republic
GRA    __
$p Charles University
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options